Microbiological evaluation demonstrates high carbapenem resistance and blaIMP gene carriage in clinical Gram-negative bacilli, highlighting emerging antimicrobial threats.
The growing prevalence of Imipenemase (IMP) metallo-beta-lactamases (MBL) producing strains of Gram-negative bacilli (GNB) pathogens is a real concern for clinicians in the light of therapeutic impasses driven. However, resistance genes encoding these enzymes are hardly documented in Burkina Faso. This study aims to show carbapenem-resistance mediated by the production of IMP-type carbapenemase in GNB clinical strains collected in Ouagadougou, Burkina Faso. Strains resistance profile to imipenem, meropenem, ertapenem, doripenem and aztreonam was determined by the disk diffusion method. Classical polymerase chain reaction (PCR) was carried out to detect β-lactamase (bla) gene of IMP in resistant strains. Out of 158 GNB collected, 91 (57.6%) were resistant to at least one of the carbapenems and/or to aztreonam. The highest prevalence of resistant strains was observed in Escherichia coli (45.1%; n=41) and Klebsiella pneumoniae (26.5% n=24). Among 32 resistant strains blaIMP gene positive (35.2%), Escherichia coli was the predominant species carrying resistance gene (18.7%, n=17/91). The findings strengthen the scarce existing scientific data on antimicrobial resistance mediated by metallo-beta-lactamases (MBL) in Burkina Faso.
No takes yet. Share an insight, caveat, or question.
Damis et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: